Clinic of Infectious Diseases, Inflammation Center, Helsinki University Hospital, Post Box 348, 00029 HUS, Helsinki, Finland.
Department of Internal Medicine, Clinicum, Medical Faculty, University of Helsinki, Helsinki, Finland.
BMC Infect Dis. 2019 Mar 18;19(1):264. doi: 10.1186/s12879-019-3890-x.
Tuberculosis (TB) is a major cause of death in HIV patients worldwide. Here we describe the epidemiology and outcome of HIV-TB co-infections in a high-income country with low TB incidence and integrated HIV and TB therapy according to European guidelines.
This study was based on the HIV cohort of the Helsinki University Hospital which includes all HIV patients in the Helsinki region with a population of 1.5 million. Totally, 1939 HIV-positives who have been under follow-up between 1998 and 2015 were included.
TB was diagnosed in 53 (2.7%) of the HIV-patients. The TB incidence rate was higher in injecting drug users (IRR 3.15; 95% CI 1.33-7.52) and heterosexuals (IRR 3.46; 95% CI 1.64-7.29) compared to men having sex with men. The incidence rate was also higher in those born in Sub-Saharan Africa (IRR 3.53; 95% CI 1.78-7.03) compared to those born in Finland. There was a significant reduction in the total TB incidence rate of 59% per 6-year period between 1998 and 2015 (p < 0.001). In injecting drug users there was a reduction in incidence rate from 1182 to 88 per 100,000 (p < 0.001) and in people born in Sub-Saharan Africa from 2017 to 195 per 100,000 (p < 0.001). Among the 53 HIV-TB co-infected cases, one female and 15 males died during follow up. HIV was the primary cause of death in five patients but none of the deaths were caused by TB.
The incidence rate of tuberculosis among HIV-positives in Finland has been declining between 1998 and 2015. Among injecting drug users, the reduction is probably explained by harm reduction interventions and care in comprehensive care centers in Helsinki. The increased coverage of antiretroviral therapy is probably another main reason for the decline in TB incidence rates. Despite good treatment results for both HIV and TB, the all-cause mortality among Finnish males with HIV-TB was high, and common causes of death were intoxications and suicides.
结核病(TB)是全球 HIV 感染者死亡的主要原因。在此,我们根据欧洲指南描述了高收入国家 HIV-TB 合并感染的流行病学和结局,该国家具有低结核病发病率和整合的 HIV 和结核病治疗。
本研究基于赫尔辛基大学医院的 HIV 队列,该队列包括赫尔辛基地区的所有 HIV 患者,人口为 150 万。共纳入了 1939 名在 1998 年至 2015 年间接受随访的 HIV 阳性患者。
53 名(2.7%)HIV 患者被诊断患有结核病。与男男性接触者相比,注射吸毒者(IRR 3.15;95%CI 1.33-7.52)和异性恋者(IRR 3.46;95%CI 1.64-7.29)的结核病发病率更高。与出生在芬兰的人相比,出生在撒哈拉以南非洲的人(IRR 3.53;95%CI 1.78-7.03)的发病率也更高。1998 年至 2015 年间,结核病总发病率每 6 年下降 59%(p<0.001)。在注射吸毒者中,发病率从每 100,000 人 1182 例降至 88 例(p<0.001),撒哈拉以南非洲出生者从 2017 年的每 100,000 人 2017 例降至 195 例(p<0.001)。在 53 例 HIV-TB 合并感染病例中,1 例女性和 15 例男性在随访期间死亡。HIV 是 5 名患者死亡的主要原因,但没有一例死亡是由结核病引起的。
1998 年至 2015 年间,芬兰 HIV 阳性者的结核病发病率一直在下降。在注射吸毒者中,减少可能归因于赫尔辛基综合护理中心的减少伤害干预措施和护理。抗逆转录病毒治疗的覆盖面增加可能是结核病发病率下降的另一个主要原因。尽管 HIV 和结核病的治疗效果良好,但芬兰男性 HIV-TB 的全因死亡率仍然很高,常见死因是中毒和自杀。